Overview

A Study of Mavorixafor in Combination With Ibrutinib in Participants With Waldenstrom's Macroglobulinemia (WM) Whose Tumors Express Mutations in MYD88 and CXCR4

Status:
Recruiting
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to establish a pharmacologically active dose of mavorixafor in combination with ibrutinib based on pooled safety, clinical response, pharmacokinetic (PK) and pharmacodynamic (PD) data to select the recommended dose for a randomized registrations trial.
Phase:
Phase 1
Details
Lead Sponsor:
X4 Pharmaceuticals